SecBot SecBot
SECBOTREPLAY Home › Report › NUVL

NUVL · GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash,…

Nuvalent, Inc. · 8-K filed Jun 9, 2026 at 07:03 ET

At the news

BULLISHIMPACT 8/10

8-K filed Jun 9, 2026 at 07:03 ET

GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion. The transaction includes two late-stage ROS1 and ALK inhibitors (zidesamtinib and neladalkib) under FDA review with 2026 target action dates, plus a phase I HER2 inhibitor. Stockholders representing ~28% of Class A shares have signed tender and support agreements to tender their shares. The deal is expected to close in Q3 2026, subject to regulatory approval and a majority-of-shares tender condition.

  • GSK to acquire Nuvalent for $124.00 per share in cash, aggregate equity value of $10.6 billion
  • Purchase price represents a 40% premium to last closing price and a 26% premium to 30-day VWAP
  • Two late-stage assets (zidesamtinib for ROS1+ NSCLC, neladalkib for ALK+ NSCLC) under FDA review with PDUFA dates of Sept 18, 2026 and Nov 27, 2026
  • Third asset NVL-330 (HER2 inhibitor) in phase I for HER2-altered NSCLC

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access